Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C

Autor: V. V. Basina, S. E. Kalach, N. V. Tyurenkova, M. E. Semenova, E. Yu. Yushina, E. G. Gordievskaya, R. A. Ganchenko, Е. V. Esaulenko
Jazyk: ruština
Rok vydání: 2019
Předmět:
Zdroj: Журнал инфектологии, Vol 11, Iss 4, Pp 65-71 (2019)
Druh dokumentu: article
ISSN: 2072-6732
DOI: 10.22625/2072-6732-2019-11-4-65-71
Popis: Objective: to analyze the efficacy and safety of using direct antiviral action drug narlaprevir/ritonavir in combination with the prolonged alpha-interferon and ribavirin drugs in the conditions of day-time hospitals of St. Petersburg and. Novgorod.Materials and methods: The study included. 35 patients with CHC of the 1st genotype. For treating these patients, a three-component regimen was used, which included the use of narlaprevir/ritonavir in combination, with peg-interferon and ribavirin.Results: among all patients included, in the study, a sustained, virological response was noted, in 85,7%. Early virological response was observed, in 91,3% cases. The recurrence rate was observed, in 10% patients. In 3 patients, therapy was interrupted, for the following reasons: due to inefficiency, the development of serious adverse events, and on its own initiative.Conclusion: the data obtained, demonstrate high, virological and. clinical efficacy and. safety of narlaprevir in combination with peg-interferon and ribavirin, in the treatment of chronic viral hepatitis C.
Databáze: Directory of Open Access Journals